Yesterday, we were talking about a new study in the Journal of the American Medical Association (JAMA) that found that proper use of prescription medicines by Part D beneficiaries is helping to reduce non-drug medical expenditures in Medicare overall. The core of the JAMA study:
Most Recent Posts
Once again, we're looking at the value of access to prescription medicines today, fueled by a study in today's Journal of the American Medical Association (subscription required).
A recent AP LifeGoesStrong.com poll found that baby boomers' (born between 1946 and 1964) health concerns are focused mostly on possible cancers and memory loss. Obviously, these are important concerns for everyone as they age.
A recent article lauding a so-called "looming wave of new generic pills," like many similar articles, fails to paint the bigger picture: that generics, while an important part of the healthcare system, ultimately play a limited role for patients.
A few weeks ago, as I was visiting my family, I took one look at my two-year-old niece and said to my sister, "Mary's diaper needs changing."
There's a geek-blog site I check out periodically. It mostly writes about science fiction and popular culture, but occasionally it takes an interesting look at real developments in the sciences and medicine.
You should check-out the piece by Ken Thorpe that recently ran in U.S. News & World Report's Health section. The piece is entitled: Health Reform That Passes the Buck Is Short-Sighted.
David Brooks has a typically thoughtful column in today's New York Times. Brooks takes a look at the roll of healthcare costs in our budget debate and opines:
When discussing progress associated with medical innovation, we like to mention both life-saving and life-enhancing medicines. Why? Because so many debilitating chronic conditions may not be life-threatening, but the patients who live with them still deserve the best that healthcare has to offer.
Monday, we discussed how policies that undercut the biopharmaceutical research sector could lead to huge job losses, with an annual reduction in sector revenue of $20 billion potentially leading to as many as 260,000 lost jobs.
It's no secret that the biopharmaceutical sector provides jobs - and a wide range of jobs, at that. We're not just researchers in lab coats. In terms of jobs we support, we're also the drivers of trucks that help medicines reach pharmacies, the construction workers and technicians who help construct the facilities and equipment necessary for manufacture of medicines, and more. Ultimately, it's an intricate web of workers that all play a role in the important work that we do.